Evidence map›Paper›PMID 37024097›Full record

ArticleCancer research and treatment2023

Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.

Kum Hei Ryu, Sunhwa Park, Jung Won Chun, Eunhae Cho, Jongmun Choi, Dong-Eun Lee, Hyoeun Shim, Yun-Hee Kim, Sung-Sik Han, Sang-Jae Park and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Kum Hei RyuCenter for Cancer Prevention and Detection, National Cancer Center, Goyang, Korea.
Sunhwa ParkTargeted Therapy Branch, Center for Rare Cancers, National Cancer Center, Goyang, Korea.
Jung Won ChunCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Eunhae ChoGC Genome, Green Cross Laboratories, Yongin, Korea.
Jongmun ChoiGC Genome, Green Cross Laboratories, Yongin, Korea.
Dong-Eun LeeBiostatics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea.
Hyoeun ShimDepartment of Laboratory Medicine, Hospital, National Cancer Center, Goyang, Korea.
Yun-Hee KimCancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
Sung-Sik HanCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Sang-Jae ParkCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Sang Myung WooCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Sun-Young KongTargeted Therapy Branch, Center for Rare Cancers, National Cancer Center, Goyang, Korea.
National Cancer Center · USNational Cancer Center · KRGreen Cross (South Korea) · KR

Funding

National Cancer Center 1910190National Cancer Center 2110181
6 · The paper itself

Abstract

purposeThe genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC. MATERIALS AND

methodsTotal of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed.

resultsPVs were detected in 20 patients (6.7%, median age 65) in ATM (n=7, 31.8%), BRCA1 (n=3, 13.6%), BRCA2 (n=3), and RAD51D (n=3). Each one patient showed TP53, PALB2, PMS2, RAD50, MSH3, and SPINK1 PV. Among them, two likely PVs were in ATM and RAD51D, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with ATM PVs and a patient with three germline PVs (BRCA2, MSH3, and RAD51D) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035).

conclusionOur study demonstrated that germline PVs in ATM, BRCA1, BRCA2, and RAD51D are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overHumansMaleMiddle AgedPrevalenceRisk FactorsTrypsin Inhibitor, Kazal PancreaticSPINK1 protein, humanTrypsin Inhibitor, Kazal PancreaticGermline pathogenic variantPancreatic ductal adenocarcinomaPrevalenceRisk factors

Identifiers

PMID37024097
PMCPMC10582541
OpenAlexW4362584158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.